What’s Cardiovascular Systems, Inc. (CSII) Upside After Today’s Significant Increase?

February 15, 2018 - By Henry Gaston

Investors sentiment decreased to 0.79 in Q3 2017. Its down 0.18, from 0.97 in 2017Q2. It dropped, as 16 investors sold Cardiovascular Systems, Inc. shares while 50 reduced holdings. 10 funds opened positions while 42 raised stakes. 24.82 million shares or 3.05% more from 24.09 million shares in 2017Q2 were reported.
Brown Cap Management Ltd Llc stated it has 2.49 million shares or 0.85% of all its holdings. 286,110 are owned by Geode Capital Mgmt Ltd Liability Company. Trexquant Investment L P reported 0.07% in Cardiovascular Systems, Inc. (NASDAQ:CSII). Wellington Mngmt Group Ltd Liability Partnership owns 2.69 million shares for 0.02% of their portfolio. 15,330 are owned by Atlantic Trust Grp Ltd Limited Liability Company. 13,509 are owned by Brown Advisory. Gotham Asset Mngmt invested in 0% or 7,296 shares. First Republic Investment Mngmt owns 13,727 shares for 0% of their portfolio. Goldman Sachs Grp Incorporated owns 0% invested in Cardiovascular Systems, Inc. (NASDAQ:CSII) for 77,102 shares. Gabelli Funds Ltd Liability Corp has 0.04% invested in Cardiovascular Systems, Inc. (NASDAQ:CSII) for 218,500 shares. Perkins Cap Mngmt reported 1.96% in Cardiovascular Systems, Inc. (NASDAQ:CSII). New York-based Metropolitan Life Insur New York has invested 0% in Cardiovascular Systems, Inc. (NASDAQ:CSII). Federated Pa holds 51,671 shares or 0% of its portfolio. Comml Bank Of Montreal Can invested in 47,891 shares or 0% of the stock. Thrivent Fin For Lutherans has invested 0.02% in Cardiovascular Systems, Inc. (NASDAQ:CSII).

The stock of Cardiovascular Systems, Inc. (NASDAQ:CSII) is a huge mover today! The stock increased 6.41% or $1.35 during the last trading session, reaching $22.4. About 821,461 shares traded or 190.98% up from the average. Cardiovascular Systems, Inc. (NASDAQ:CSII) has risen 113.78% since February 15, 2017 and is uptrending. It has outperformed by 97.08% the S&P500.
The move comes after 8 months positive chart setup for the $744.09M company. It was reported on Feb, 15 by Barchart.com. We have $24.42 PT which if reached, will make NASDAQ:CSII worth $66.97M more.

Cardiovascular Systems, Inc. (NASDAQ:CSII) Ratings Coverage

Among 9 analysts covering Cardiovascular Systems (NASDAQ:CSII), 4 have Buy rating, 2 Sell and 3 Hold. Therefore 44% are positive. Cardiovascular Systems had 25 analyst reports since August 6, 2015 according to SRatingsIntel. Needham downgraded the stock to “Underperform” rating in Friday, January 22 report. The rating was initiated by Lake Street with “Buy” on Monday, January 30. The firm has “Outperform” rating by Leerink Swann given on Thursday, February 8. The stock of Cardiovascular Systems, Inc. (NASDAQ:CSII) has “Sell” rating given on Friday, August 21 by Zacks. Bank of America downgraded the stock to “Underperform” rating in Thursday, October 8 report. Bank of America upgraded the shares of CSII in report on Thursday, August 4 to “Neutral” rating. The firm has “Buy” rating given on Thursday, January 26 by Needham. The rating was upgraded by Needham to “Buy” on Friday, April 1. Needham downgraded Cardiovascular Systems, Inc. (NASDAQ:CSII) on Friday, December 15 to “Hold” rating. The rating was maintained by Needham with “Buy” on Wednesday, June 29.

More important recent Cardiovascular Systems, Inc. (NASDAQ:CSII) news were published by: Businesswire.com which released: “Cardiovascular Systems, Inc. Appoints Jeff Points as Chief Financial Officer” on February 07, 2018, also Businesswire.com published article titled: “Cardiovascular Systems Expands Product Portfolio to Further Support Peripheral …”, Businesswire.com published: “Cardiovascular Systems, Inc. Announces First Patients Treated from Radial …” on February 14, 2018. More interesting news about Cardiovascular Systems, Inc. (NASDAQ:CSII) was released by: Bizjournals.com and their article: “Cardiovascular Systems Inc. appoints Rhonda Robb as chief operating officer” with publication date: January 24, 2018.

Cardiovascular Systems, Inc., a medical technology company, develops, makes, and markets devices to treat vascular diseases in the United States. The company has market cap of $744.09 million. The firm offers peripheral arterial disease products, including Diamondback 360 Peripheral Orbital Atherectomy System , Diamondback 360 60cm Peripheral OAS, Diamondback 360 4 French 1.25 Peripheral OAS, Diamondback 360 1.50 Peripheral OAS, Diamondback 360 2.00 Peripheral OAS, and Stealth 360 Peripheral OAS, which are catheter platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives. It currently has negative earnings. It also provides Diamondback 360 Coronary OAS, an atherectomy device for the treatment of calcified coronary arteries.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.